Early evidence: hypocapnia and cerebral hypoperfusion during tilt
In 1998, Novak and colleagues published a paper in Stroke — one of the highest-impact journals in neurology — demonstrating that orthostatic intolerance involves cerebral blood flow reduction and CO₂ dysregulation that occur independently of heart rate and blood pressure thresholds. The methodology was in place. The findings were clear. The publication was in a prominent journal. And the clinical practice of evaluating orthostatic intolerance with a tilt table, a heart rate monitor, and an arm cuff continued unchanged into the next decade, and the decade after that. In 2025, most patients with orthostatic intolerance symptoms are still evaluated with protocols that ignore evidence published when the internet was in its early commercial phase. This paper is not cited here because of what it found in isolation. It is cited because of what it proves about the distance between published evidence and clinical practice in dysautonomia care.
What the 1998 Paper Measured
Novak and colleagues recruited patients with documented orthostatic intolerance and subjected them to head-up tilt table testing. The key methodological addition was simultaneous measurement of middle cerebral artery blood flow velocity using transcranial Doppler and end-tidal CO₂ using capnography, alongside standard heart rate and blood pressure monitoring. This combination allowed the researchers to observe what was happening in the cerebral circulation and the CO₂ environment during the same tilt challenge that standard monitoring was evaluating through peripheral vital signs.
The findings established three things simultaneously. First, that cerebral blood flow velocity fell during tilt in orthostatic intolerance patients — the brain was receiving less blood when upright. Second, that CO₂ fell during tilt in these patients — the arterial CO₂ concentration dropped as tilt proceeded, indicating hyperventilation or respiratory pattern changes triggered by the orthostatic challenge. Third, that the two were connected: the CO₂ reduction was driving cerebral blood vessel constriction through the well-established cerebrovascular reactivity mechanism, and this vasoconstriction was contributing to the cerebral blood flow reduction. The peripheral vital signs, monitored simultaneously, did not capture any of this.
The CO₂ Reversal Experiment: Mechanism, Not Correlation
The most definitive finding in the Novak 1998 paper was not the observation of CO₂ reduction and cerebral hypoperfusion during tilt — though that was important — but the reversal experiment. During tilt, when patients were given CO₂-enriched air to breathe, two things happened. Cerebral blood flow velocity increased as the CO₂ restored cerebral arteriolar tone and reduced vasoconstriction. And symptoms improved. Patients who had been experiencing dizziness, cognitive difficulty, and presyncope during tilt reported improvement when cerebral blood flow was restored through CO₂ supplementation.
This is not a correlation. It is a mechanism demonstration. The experiment followed the standard logic of physiological causality: identify a variable that changes (CO₂ falls), predict the downstream effect (cerebral vasoconstriction and reduced cerebral blood flow), intervene to restore the variable (provide CO₂ supplement), observe reversal of the downstream effect (cerebral blood flow increases), and document symptom improvement. The CO₂-cerebral blood flow-symptom chain was demonstrated bidirectionally. CO₂ falling caused the problem. CO₂ being restored resolved it. Later research by Stewart and colleagues confirmed this same reversal in POTS patients almost two decades later, using CO₂ inhalation to reverse tilt-induced cerebral hypoperfusion — repeating and extending what Novak had already established in 1998.
The Self-Perpetuating Cycle of Hypocapnia and Hypoperfusion
The Novak 1998 findings point to a mechanism that is self-reinforcing once initiated. When a patient with orthostatic intolerance stands, gravitational blood pooling reduces venous return and cardiac output. The brain receives less blood. The brain's response to potential oxygen insufficiency includes increased respiratory drive — breathing faster to increase oxygen intake. But this increased breathing also blows off CO₂. The CO₂ reduction then triggers cerebrovascular constriction, reducing cerebral blood flow further. The additional cerebral hypoperfusion increases the neurological stress signal, which can further elevate respiratory drive, blowing off more CO₂. The cycle can amplify itself.
This is not a theoretical mechanism constructed to explain the findings post-hoc. It is the direct implication of established cerebrovascular physiology applied to the orthostatic context. The CO₂-cerebrovascular reactivity relationship is among the best-characterized mechanisms in cerebrovascular physiology. The connection between gravitational hemodynamic challenge and respiratory pattern changes in susceptible patients was already understood. The 1998 Novak paper put these two elements together in patients with orthostatic intolerance and showed that they were both present and mechanistically connected in this population. The progression from hypocapnia to cerebral blood flow collapse is the mechanism behind syncope itself — the 1998 findings placed orthostatic intolerance symptoms within the same physiological chain, at a less extreme degree of the same process.
A Standards Failure, Not a Knowledge Gap
The research demonstrating that CO₂ and cerebral blood flow are central to orthostatic intolerance physiology did not begin with a recent paper and need to work its way into clinical practice. It was published in a neurology journal of record in 1998. The 2014 Lewis review synthesized the accumulated evidence and made the explicit argument that CO₂ monitoring belongs in orthostatic evaluation. The 2017 Norcliffe-Kaufmann standards paper established TCD as the appropriate tool for direct cerebral perfusion measurement in autonomic testing. The evidence chain is long, consistent, and published across decades in credible journals.
Standard clinical tilt testing in 2025 still does not routinely include CO₂ monitoring or transcranial Doppler in most centers. The evaluation that most patients with orthostatic intolerance receive consists of the same heart rate and blood pressure monitoring that was already insufficient when the 1998 paper was published. The gap between the evidence and clinical practice is not a knowledge gap in the research community. The researchers know. The tools are described. The mechanisms are established. The interventions that follow from understanding those mechanisms — breathing retraining, CO₂-aware management, TCD-guided evaluation — are available. The gap is a standards failure: a failure of clinical guidelines and practice protocols to incorporate evidence that has been in the peer-reviewed literature for more than a quarter of a century.
What 27 Years of Ignored Evidence Means for Patients
For patients currently being evaluated for orthostatic intolerance symptoms, the 1998 Novak paper is not just a historical reference. It is evidence that the tools capable of identifying the mechanism driving their symptoms have been validated since before many of them were diagnosed. When a patient undergoes a standard tilt test in 2025 that includes only heart rate and blood pressure monitoring, they are being evaluated with a protocol that ignores published evidence from 1998, 2014, 2017, 2018, 2019, and 2020 — a continuous chain of research establishing that the measurements being taken are insufficient to detect the mechanisms being evaluated.
Orthostatic intolerance is a brain perfusion problem. The evidence for this has existed since at least 1998. The evaluation tool that measures brain perfusion directly during orthostatic challenge — transcranial Doppler — has been validated and described in the research literature for decades. The question a patient should bring to their evaluating clinician after a standard tilt test is not whether the results were positive or negative by heart rate and blood pressure criteria. It is whether cerebral blood flow was measured during the test. If it was not, the evaluation did not assess the central variable of the condition being evaluated. That is not a controversial statement. It is a direct implication of evidence that has been in the literature since the same year Google was founded.